Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.

Younis, Islam R; Hsueh, Chia-Hsiang; Nelson, Cara; Billin, Andrew N; Yue, Mun Sang; Xiao, Deqing; Watkins, Timothy R; Othman, Ahmed A

Younis, Islam R; Hsueh, Chia-Hsiang; Nelson, Cara; Billin, Andrew N; Yue, Mun Sang; Xiao, Deqing; Watkins, Timothy R; Othman, Ahmed A.

Afiliación

Younis IR; Gilead Sciences Inc, Foster City, California, USA.
Hsueh CH; Gilead Sciences Inc, Foster City, California, USA.
Nelson C; Gilead Sciences Inc, Foster City, California, USA.
Billin AN; Gilead Sciences Inc, Foster City, California, USA.
Yue MS; Gilead Sciences Inc, Foster City, California, USA.
Xiao D; Gilead Sciences Inc, Foster City, California, USA.
Watkins TR; Gilead Sciences Inc, Foster City, California, USA.
Othman AA; Gilead Sciences Inc, Foster City, California, USA.

J Clin Pharmacol ; 63(9): 1017-1025, 2023 09.

Article en En | MEDLINE | ID: mdl-37128693

Asunto(s)

Hepatopatías; Humanos; Área Bajo la Curva; Hepatopatías/metabolismo

Palabras clave

cilofexor; hepatic impairment; pharmacodynamics; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatopatías Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google